Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Size: px
Start display at page:

Download "Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational"

Transcription

1 Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational

2 Clinical Trial Results Database Page 3 Study Number CA2220 Title A randomized, double-blind, placebo controlled, multicenter dose ranging study of subcutaneously administered secukinumab (), assessing Psoriasis Area and Severity Index (PASI) response in patients with moderate to severe chronic plaque-type psoriasis Phase of Development II Study Start/End Dates 01-Mar-2010 / 14-Feb-2011 Study Design/Methodology This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with moderate to severe chronic plaque-type psoriasis. The study consisted of 3 periods: screening, treatment and follow up. The screening period of up to 4 weeks was used to assess eligibility of the patients and taper patients off disallowed medications. Eligible patients were randomized in a ratio of 1:1:1:1:1 to either placebo or one of 4 different regimens of secukinumab (monthly dosing of 25 mg, 75 mg or 150 mg, or a single dose of 25 mg). Randomization was stratified according to body weight (< 90 kg or 90 kg).

3 Clinical Trial Results Database Page 4 Centres A total of 19 centers in 6 countries: Canada (3 centers), Estonia (3), Iceland (1), Japan (4), Latvia (3) and United States (5). Publication NA

4 Clinical Trial Results Database Page 5 Objectives Primary objective(s) To assess the efficacy of three different doses of s.c. administered monthly (25 mg, 75 mg and 150 mg) or as a single administration (25 mg) in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 achievement 12 weeks after start of treatment, compared to placebo Secondary objective(s) To evaluate treatment success as assessed by the Investigator s Global Assessment (static IGA) 12 weeks after start of treatment To evaluate the efficacy of the three different doses administered monthly as well as the single dosing at 12 weeks after start of treatment To assess the time to relapse To measure the effect of on PASI over time To investigate the safety and tolerability Test Product (s), Dose(s), and Mode(s) of Administration Secukinumab mg: secukinumab 150 mg s.c. administered at weeks 1, 5, and 9 Secukinumab 3 75 mg: secukinumab 75 mg s.c. administered at weeks 1, 5, and 9 Secukinumab 3 25 mg: secukinumab 25 mg s.c. administered at weeks 1, 5, and 9 Secukinumab 1 25 mg: secukinumab 25 mg s.c. administered at week 1, and placebo s.c. administered at weeks 5 and 9

5 Clinical Trial Results Database Page 6 Reference Product(s), Dose(s), and Mode(s) of Administration Placebo: placebo s.c. administered at weeks 1, 5, and 9 Criteria for Evaluation Primary variables Improvement of Psoriasis Area and Severity Index (PASI) score Secondary variables Investigator s global assessment (IGA) Safety and tolerability Hematology, blood chemistry and urinalysis Vital signs ECG Immunogenicity Pharmacology Pharmacokinetic samplings Other NA Statistical Methods The randomized set included all 125 patients randomized to treatment. The full analysis set (FAS), identical to the randomized set, also consisted of all randomized patients. For both sets, patients were analyzed according to the treatment and body weight stratum (i.e. 90 or < 90 kg) assigned at randomization. The safety set included all patients who took at least one dose of study drug and had at least one post-baseline safety assessment. All efficacy analyses were based on the FAS. The safety analyses were based on the safety set. Patient disposition, protocol deviations, demographic and baseline data, relevant medical histories and continuing medical conditions and exposure to study drug were summarized by treatment group and listed. Concomitant medications and significant non-drug therapies were coded by the ATC classification, summarized by treatment and listed. MedDRA version 13.1 was used for coding of medical history/co-existing disease and AEs/SAEs. The primary efficacy variable was PASI 75 response, i.e., the 75% improvement (reduction) in PASI score compared to baseline (i.e. treatment response). The primary endpoint, achievement of PASI 75 at Week 13, was analyzed by means of the stratified Cochran-Mantel-Haenszel (CMH) with region and body weight (< 90 kg, 90 kg) as strata. Results were presented with odds ratio,

6 Clinical Trial Results Database Page 7 95% confidence interval (CI), and two-sided p-values for all contrasts versus placebo. If a patient s total PASI score was missing at any visit after baseline, the missing score was imputed by the last observation carried forward, LOCF, method. Missing post-baseline data of the IGA score (overall psoriatic disease as well as involvement of hands and feet) were imputed in the same way as the PASI score. Supportive analysis of the primary efficacy variable consisted of logistic regression of PASI 75 response at Week 13. The model accounted for treatment group, region, body weight stratum and baseline PASI. The key secondary efficacy endpoint was IGA treatment response at Week 13 (for overall psoriatic disease) which was analyzed by descriptive statistics, stratified CMH test and logistic regression, as described for the primary endpoint. Other secondary efficacy endpoints were analyzed by descriptive statistics and logistic regression, where appropriate. Plots and corresponding tables of Kaplan-Meier estimates for probability of time to relapse were provided by active treatment group. Shift tables for the shift from baseline to the best assessment (i.e. lowest IGA) during treatment period were provided. Subgroup analyses of the primary efficacy and secondary endpoints were performed for body weight (< 90 kg, 90 kg), region (Japan, other than Japan), psoriatic arthritis at screening, previous systemic psoriasis therapy, previous biologic psoriasis therapy and previous psoriasis UV therapy. All AEs, SAEs and deaths were summarized overall and by treatment group. Potential risks were defined based on AEs (infections; malignancies; hypersensitivity, infusion and local site reations; lack of efficacy/worsening of underlying disease; antibody development and immunogenicity; and risk during pregnancy). Relative risks were calculated (as ratio of percentages) with 95% CIs for each potential risk. In addition, the potential risk 'Infections' was summarized separately. Time to infection as analyzed using stratified log-rank tests (stratified by body weight group). Each active treatment group was compared to placebo. Plots and corresponding tables of Kaplan Meier estimates of time to infection were provided by treatment group. Subgroup analyses were performed for region. Laboratory data were summarized by treatment group and listed. Shift tables using normal ranges from the central laboratory and box-plots for selected laboratory parameters were provided. Vital signs were summarized with standard descriptive statistics for absolute values and changes from baseline by treatment group and visit. Patients with clinically notable abnormalities in laboratory values or vital signs were summarized. Summary statistics were provided for anti- antibodies as well as for the binary assessment of immunogenicity (yes/no), by treatment group and visit. Study Population: Inclusion/Exclusion Criteria and Demographics Main Inclusion Criteria: Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization At randomization, moderate to severe psoriasis as defined by: o PASI score of 12 or greater and, o IGA score of 3 or greater and, o Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater At screening and randomization, chronic plaque-type psoriasis considered inadequately controlled by topical treatment Main Exclusion Criteria: Forms of psoriasis other than chronic plaque-type

7 Clinical Trial Results Database Page 8 Drug-induced psoriasis (e.g., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium) at randomization Previous exposure to Ongoing use of prohibited psoriasis treatments / medications and other prohibited medication at randomization. Washout periods detailed in the protocol have to be adhered to Known immunosuppression (e.g., AIDS) at screening and / or randomization History or evidence of active tuberculosis at screening Active systemic infections (other than common cold) History or symptoms of malignancy of any organ system, treated or untreated, within the past 5 years. Any severe, progressive or uncontrolled medical condition at randomization that in the judgment of the investigator prevents the patient from participating in the study Any clinically significant abnormal laboratory tests at randomization, that in the judgment of the investigator prevents the patient from participating in the study Inability or unwillingness to undergo repeated venipuntures History or evidence of drug or alcohol abuse Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply

8 Clinical Trial Results Database Page 9 Number of Subjects 1x25 mg 3x150 mg Placebo Total Planned N Randomized 29 (100.0) 26 (100.0) 21 (100.0) 27 (100.0) 22 (100.0) 125 (100.0) Randomized and treated 29 (100.0) 26 (100.0) 21 (100.0) 27 (100.0) 22 (100.0) 125 (100.0) Completed 14 (48.3) 16 (61.5) 17 (81.0) 20 (74.1) 11 (50.0) 78 (62.4) Discontinued 15 (51.7) 10 (38.5) 4 (19.0) 7 (25.9) 11 (50.0) 47 (37.6) Primary reason for premature discontinuation Unsatisfactory therapeutic effect 4 (13.8) 6 (23.1) 2 (9.5) 0 6 (27.3) 18 (14.4) Subject withdrew consent 8 (27.6) 2 (7.7) 1 (4.8) 2 (7.4) 3 (13.6) 16 (12.8) Administrative problems 1 (3.4) 1 (3.8) 0 2 (7.4) 1 (4.5) 5 (4.0) Lost to follow-up 1 (3.4) 0 1 (4.8) 2 (7.4) 0 4 (3.2) Adverse Event(s) 1 (3.4) 1 (3.8) 0 1 (3.7) 0 3 (2.4) Death (4.5) 1 (0.8) Demographic and Background Characteristics 1x25 mg N=29 N=26 N=21 3x150 mg N=27 Placebo N=22 Total N=125 Mean Age (years) Male 20 (69.0) 22 (84.6) 14 (66.7) 21 (77.8) 14 (63.6) 91 (72.8) Female 9 (31.0) 4 (15.4) 7 (33.3) 6 (22.2) 8 (36.4) 34 (27.2) Race - Caucasian 24 (82.8) 20 (76.9) 15 (71.4) 20 (74.1) 17 (77.3) 96 (76.8) Asian 4 (13.8) 6 (23.1) 5 (23.8) 7 (25.9) 5 (22.7) 27 (21.6) Other 1 (3.4) 0 1 (4.8) (1.6) Mean weight (kg) Mean PASI score Primary Objective Result(s) PASI 75 achievement at Week 13: number (%) of responders and treatment comparisons vs. placebo (Full analysis set, LOCF) Treatment Group Number (%) of PASI 75 responders at Week 13 p-value (CMH test) 1x25 mg (N=29) 1 (3.4) vs. placebo (N=26) 5 (19.2) vs. placebo (N=21) 12 (57.1) vs. placebo x150 mg (N=27) 22 (81.5) vs. placebo <0.001

9 Clinical Trial Results Database Page 10 Placebo (N=22) 2 (9.1)

10 Clinical Trial Results Database Page 11 Secondary Objective Result(s) Investigator s Global Assessment (IGA) by visit and treatment (Full analysis set, LOCF) Visit Statistic 1x25 mg N=29 N=26 N=21 3x150 mg N=27 Placebo N=22 Week 2 n evaluable Response, (3.7) 0 Week 3 n evaluable Response, (3.7) 0 Week 5 n evaluable Response, 0 1 (3.8) 1 (4.8) 2 (7.4) 0 Week 9 n evaluable Response, 0 2 (7.7) 6 (28.6) 10 (37.0) 2 (9.1) Week 13 n evaluable Response, 0 3 (11.5) 7 (33.3) 13 (48.1) 2 (9.1) Week 17 n evaluable Response, 1 (3.4) 5 (19.2) 6 (28.6) 14 (51.9) 2 (9.1) Week 21 n evaluable Response, 0 5 (19.2) 8 (38.1) 11 (40.7) 3 (13.6) Week 25 n evaluable Response, 0 4 (15.4) 7 (33.3) 10 (37.0) 4 (18.2) Week 29 n evaluable Response, 0 3 (11.5) 4 (19.0) 11 (40.7) 3 (13.6) Week 33 n evaluable Response, 0 4 (15.4) 4 (19.0) 8 (29.6) 0 Week 37 n evaluable Response, 0 4 (15.4) 2 (9.5) 7 (25.9) 0 Treatment response was defined as an IGA score of 0 (clear) or 1 (almost clear) and improvement of at least 2 points on the IGA scale compared to baseline. Number (%) of patients achieving PASI 50, PASI 75, or PASI 90 by visit and treatment (Full analysis set, LOCF) Visit Criterion 1x25 mg N=29 N=26 N=21 3x150 mg N=27 Placebo N=22 Week 2 n evaluable PASI 50 1 (3.4) 2 (7.7) 1 (4.8) 3 (11.1) 0 PASI PASI Week 3 n evaluable PASI 50 1 (3.4) 2 (7.7) 5 (23.8) 5 (18.5) 1 (4.5) PASI PASI Week 5 n evaluable PASI 50 3 (10.3) 4 (15.4) 6 (28.6) 13 (48.1) 1 (4.5)

11 Clinical Trial Results Database Page 12 PASI (7.7) 1 (4.8) 4 (14.8) 1 (4.5) PASI (3.7) 0 Week 9 n evaluable PASI 50 3 (10.3) 10 (38.5) 11 (52.4) 23 (85.2) 3 (13.6) PASI 75 1 (3.4) 3 (11.5) 7 (33.3) 18 (66.7) 2 (9.1) PASI (3.8) 2 (9.5) 4 (14.8) 0 Week 13 n evaluable PASI 50 5 (17.2) 15 (57.7) 17 (81.0) 23 (85.2) 4 (18.2) PASI 75 1 (3.4) 5 (19.2) 12 (57.1) 22 (81.5) 2 (9.1) PASI (7.7) 4 (19.0) 14 (51.9) 1 (4.5) Week 17 n evaluable PASI 50 6 (20.7) 14 (53.8) 16 (76.2) 23 (85.2) 6 (27.3) PASI 75 2 (6.9) 7 (26.9) 9 (42.9) 22 (81.5) 3 (13.6) PASI (15.4) 2 (9.5) 12 (44.4) 0 Week 21 n evaluable PASI 50 4 (13.8) 13 (50.0) 12 (57.1) 23 (85.2) 7 (31.8) PASI (23.1) 8 (38.1) 21 (77.8) 3 (13.6) PASI (15.4) 2 (9.5) 10 (37.0) 1 (4.5) Week 25 n evaluable PASI 50 4 (13.8) 13 (50.0) 12 (57.1) 23 (85.2) 7 (31.8) PASI (19.2) 7 (33.3) 19 (70.4) 2 (9.1) PASI (11.5) 4 (19.0) 8 (29.6) 1 (4.5) Week 29 n evaluable PASI 50 5 (17.2) 12 (46.2) 11 (52.4) 23 (85.2) 6 (27.3) PASI (15.4) 5 (23.8) 16 (59.3) 3 (13.6) PASI (7.7) 3 (14.3) 6 (22.2) 2 (9.1) Week 33 n evaluable PASI 50 3 (10.3) 9 (34.6) 10 (47.6) 21 (77.8) 5 (22.7) PASI 75 1 (3.4) 5 (19.2) 5 (23.8) 15 (55.6) 1 (4.5) PASI (9.5) 5 (18.5) 1 (4.5) Week 37 n evaluable PASI 50 5 (17.2) 8 (30.8) 10 (47.6) 17 (63.0) 5 (22.7) PASI 75 1 (3.4) 5 (19.2) 4 (19.0) 7 (25.9) 1 (4.5) PASI (3.8) 2 (9.5) 3 (11.1) 1 (4.5) Time to relapse, by treatment (LOCF) 1x25 mg N=29 N=26 N=21 Subjects in Analysis Subjects with the event Event rate (%) Median Time to relapse (days) NE NE NE

12 Clinical Trial Results Database Page 13 Safety Results Adverse events by primary system organ class (Safety set) Primary system organ class 1x25 mg N=29 N=26 N=21 3x150 mg N=27 Placebo N=22 Total N=125 Patients with any AE(s) 22 (75.9) 19 (73.1) 16 (76.2) 24 (88.9) 16 (72.7) 97 (77.6) Blood and lymphatic system disorders 0 1 (3.8) 0 1 (3.7) 0 2 (1.6) Cardiac disorders 1 (3.4) 1 (3.8) 1 (4.8) 0 3 (13.6) 6 (4.8) Congenital, familial and genetic 0 1 (3.8) (0.8) disorders Ear and labyrinth disorders 2 (6.9) 1 (3.8) (2.4) Endocrine disorders (4.5) 1 (0.8) Eye disorders 0 1 (3.8) 0 1 (3.7) 0 2 (1.6) Gastrointestinal disorders 2 (6.9) 5 (19.2) 3 (14.3) 3 (11.1) 1 (4.5) 14 (11.2) General disorders and administration 0 1 (3.8) 0 6 (22.2) 2 (9.1) 9 (7.2) site conditions Hepatobiliary disorders (3.7) 0 1 (0.8) Immune system disorders 0 2 (7.7) 0 1 (3.7) 1 (4.5) 4 (3.2) Infections and infestations 9 (31.0) 12 (46.2) 10 (47.6) 12 (44.4) 8 (36.4) 51 (40.8) Injury, poisoning and procedural 1 (3.4) 1 (3.8) 0 5 (18.5) 2 (9.1) 9 (7.2) complications Investigations 1 (3.4) 1 (3.8) 2 (9.5) 1 (3.7) 1 (4.5) 6 (4.8) Metabolism and nutrition disorders 1 (3.4) 1 (3.8) (4.5) 3 (2.4) Musculoskeletal and connective 4 (13.8) 4 (15.4) 4 (19.0) 3 (11.1) 2 (9.1) 17 (13.6) tissue disorders Neoplasms benign, malignant and (3.7) 0 1 (0.8) unspecified (incl cysts and polyps) Nervous system disorders 1 (3.4) 4 (15.4) 2 (9.5) 2 (7.4) 0 9 (7.2) Pregnancy, puerperium and perinatal (4.5) 1 (0.8) conditions Psychiatric disorders 0 2 (7.7) (1.6) Renal and urinary disorders 0 1 (3.8) (0.8) Respiratory, thoracic and mediastinal 2 (6.9) 4 (15.4) 1 (4.8) 1 (3.7) 1 (4.5) 9 (7.2) disorders Skin and subcutaneous tissue disorders 9 (31.0) 5 (19.2) 5 (23.8) 5 (18.5) 7 (31.8) 31 (24.8) Social circumstances (3.7) 0 1 (0.8) Vascular disorders 1 (3.4) 2 (7.7) 0 2 (7.4) 0 5 (4.0) Primary system organ classes are sorted alphabetically

13 Clinical Trial Results Database Page 14 Most frequent adverse events (at least 5% in any treatment group) by preferred term and treatment group (Safety set) Preferred term 1x25 mg N=29 N=26 N=21 3x150 mg N=27 Placebo N=22 Total N=125 Patients with any AE(s) 22 (75.9) 19 (73.1) 16 (76.2) 24 (88.9) 16 (72.7) 97 (77.6) Psoriasis* 8 (27.6) 4 (15.4) 4 (19.0) 3 (11.1) 2 (9.1) 21 (16.8) Nasopharyngitis 1 (3.4) 4 (15.4) 4 (19.0) 4 (14.8) 2 (9.1) 15 (12.0) Upper respiratory tract infection 3 (10.3) 2 (7.7) 1 (4.8) 2 (7.4) 0 8 (6.4) Headache 1 (3.4) 2 (7.7) 1 (4.8) 1 (3.7) 0 5 (4.0) Pruritus 1 (3.4) (3.7) 3 (13.6) 5 (4.0) Respiratory tract infection viral 1 (3.4) 1 (3.8) 1 (4.8) 0 2 (9.1) 5 (4.0) Back pain 0 1 (3.8) 2 (9.5) 1 (3.7) 0 4 (3.2) Fatigue (11.1) 1 (4.5) 4 (3.2) Hypertension 1 (3.4) 1 (3.8) 0 2 (7.4) 0 4 (3.2) Muscle strain 1 (3.4) (7.4) 0 3 (2.4) Myalgia 2 (6.9) (4.5) 3 (2.4) Edema peripheral (7.4) 1 (4.5) 3 (2.4) Pharyngitis 0 1 (3.8) 0 2 (7.4) 0 3 (2.4) Preferred terms are presented in descending order of frequency in the total column. Deaths, other serious adverse events and adverse events leading to discontinuation of study drug by treatment group (Safety set) 1x25 mg N=29 N=26 N=21 3x150 mg N=27 Placebo N=22 Total N=125 Patients with any AE(s) 22 (75.9) 19 (73.1) 16 (76.2) 24 (88.9) 16 (72.7) 97 (77.6) Death(s) (4.5) 1 (0.8) SAE(s) 0 2 (7.7) 1 (4.8) 0 2 (9.1) 5 (4.0) Discontinued due to AE(s) 0 1 (3.8) 0 1 (3.7) 0 2 (1.6) Other Relevant Findings NA

14 Clinical Trial Results Database Page 15 Date of Clinical Trial Report 02 February 2012 Date Inclusion on Novartis Clinical Trial Results Database 24 February 2012 Date of Latest Update

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use

More information

Coding with MedDRA. MedDRA and the MSSO

Coding with MedDRA. MedDRA and the MSSO Coding with MedDRA MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) MedDRA and the MSSO International support and development of

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Phase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008

Phase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Trial Description. Organizational Data. Secondary IDs

Trial Description. Organizational Data. Secondary IDs Trial Description Title A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel in patients

More information

ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close

ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close Home > Record Summary > Results Section ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close Hide All Participant Flow Participants

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page Sponsor Novartis Generic Drug Name BGT6 Therapeutic Area of Trial Advanced solid malignancies Approved Indication Investigational Study Number CBGT6A0 Title A phase

More information

Humulin (LY041001) Page 1 of 1

Humulin (LY041001) Page 1 of 1 (LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CICL670A2202 Previous Study Return to List Next Study Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload

More information

Mortality statistics and road traffic accidents in the UK

Mortality statistics and road traffic accidents in the UK Mortality statistics and road traffic accidents in the UK An RAC Foundation Briefing Note for the UN Decade of Action for Road Safety In 2009 2,605 people died in road traffic accidents in the UK. While

More information

Sponsor Novartis. Generic Drug Name Fingolimod. Therapeutic Area of Trial Relapsing forms of multiple sclerosis

Sponsor Novartis. Generic Drug Name Fingolimod. Therapeutic Area of Trial Relapsing forms of multiple sclerosis Sponsor Novartis Generic Drug Name Fingolimod Therapeutic Area of Trial Relapsing forms of multiple sclerosis Approved Indication(s) United States (US Package Insert) Fingoliomod is indicated for the treatment

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract

More information

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Guidance for Industry Migraine: Developing Drugs for Acute Treatment

Guidance for Industry Migraine: Developing Drugs for Acute Treatment Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

Mr. Wenning, Dr. Dekkert, Please find the letter of Mrs Valerie Williams regarding your behaviour at the assembly, which I do consent upon entirely.

Mr. Wenning, Dr. Dekkert, Please find the letter of Mrs Valerie Williams regarding your behaviour at the assembly, which I do consent upon entirely. medical ethics Alfelderstr. 9 31139 Hildesheim Bayer AG Chairman of the Advisory Board Mr. Werner Wenning Chairman of the Board of Directors Dr. Marjin Dekkert. Kaiser Wilhel- Alee 1 51368 Leverkusen medical

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form. General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary

More information

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511351:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: CR002353 Johnson & Johnson Pharmaceutical

More information

Riociguat Clinical Trial Program

Riociguat Clinical Trial Program Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine

More information

Immunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020

Immunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020 Page 020 4.0 Efficacy of Mitoxantrone in Multiple Sclerosis The efficacy of mitoxantrone in MS was demonstrated in two well-designed, randomized trials: Studies 901 and 902. The study design and efficacy

More information

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence 1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,

More information

SUPPLEMENTARY MATERIALS. Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial

SUPPLEMENTARY MATERIALS. Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial 1 SUPPLEMENTARY MATERIALS Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial Professor Ka Sing Lawrence Wong on behalf of The Executive Steering Committee and the ROCKET

More information

Summary of the risk management plan (RMP) for Otezla (apremilast)

Summary of the risk management plan (RMP) for Otezla (apremilast) EMA/741412/2014 Summary of the risk management plan (RMP) for Otezla (apremilast) This is a summary of the risk management plan (RMP) for Otezla, which details the measures to be taken in order to ensure

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

ICD 10 ICD 9. 14, 000 codes No laterality Limited severity parameters No placeholders 3-5 digits

ICD 10 ICD 9. 14, 000 codes No laterality Limited severity parameters No placeholders 3-5 digits ICD 10 Conversion 1 Why Change? ICD 9 14, 000 codes No laterality Limited severity parameters No placeholders 3-5 digits 1 2 3 4 5 ICD 10 69,000+ codes Indicates Rt or Lt Extensive severity parameters

More information

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment

More information

C CS. California Children Services Alameda County

C CS. California Children Services Alameda County C CS California Children Services Alameda County The California Children Services (CCS) Program strives to assure access to medical services essential to the health and well-being of children with catastrophic

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for

More information

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR. 2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title

More information

ICD-10 in the Provider Newsletter

ICD-10 in the Provider Newsletter ICD-10 in the Provider Newsletter ICD-10 CM Code Structure, July 2013 ICD-10 Implementation, April 2013 ICD-10 Manual, January 2013 ICD-10 Back on Track, October 2012 ICD-10 Training, July 2012 ICD-10

More information

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Objective: To investigate the hepatic clearance of NRL972 in patients undergoing alcohol withdrawal therapy

Objective: To investigate the hepatic clearance of NRL972 in patients undergoing alcohol withdrawal therapy Title of the Study: A multi-centre, open, short term follow-up Phase II study to evaluate the clearance of NRL972 in patients undergoing alcohol withdrawal commencing in a controlled clinical setting Short

More information

CHARGES FOR DRUG-RELATED INPATIENT HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS IN KENTUCKY, 2009-2013

CHARGES FOR DRUG-RELATED INPATIENT HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS IN KENTUCKY, 2009-2013 CHARGES FOR DRUG-RELATED INPATIENT HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS IN KENTUCKY, 2009-2013 Prepared for the Kentucky Injury Prevention & Research Center by: Huong Luu, MD, MPH W. Jay Christian,

More information

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review

More information

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields

More information

Antipsychotic drugs are the cornerstone of treatment

Antipsychotic drugs are the cornerstone of treatment Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,

More information

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Non-covered ICD-10-CM Codes for All Lab NCDs

Non-covered ICD-10-CM Codes for All Lab NCDs Non-covered ICD-10-CM s for All Lab NCDs This section lists codes that are never covered by Medicare for a diagnostic lab testing service. If a code from this section is given as the reason for the test,

More information

CCS Statewide CY2012 Fee for Service Expenditures by Claim Type and Diagnosis Duplicate CIN Count Claim Type Code Desc DX Group DX SubGroup Sum of

CCS Statewide CY2012 Fee for Service Expenditures by Claim Type and Diagnosis Duplicate CIN Count Claim Type Code Desc DX Group DX SubGroup Sum of CCS Statewide CY2012 Fee for Service Expenditures by Claim Type and Diagnosis Duplicate CIN Count Claim Type Code Desc DX Group DX SubGroup Sum of Medi-Cal Reimbursement * Outpatient Supplementary V Codes

More information

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population

More information

Using the ICD-10-CM. The Alphabetic Index helps you determine which section to refer to in the Tabular List. It does not always provide the full code.

Using the ICD-10-CM. The Alphabetic Index helps you determine which section to refer to in the Tabular List. It does not always provide the full code. Using the ICD-10-CM Selecting the Correct Code To determine the correct International Classification of Diseases, 10 Edition, Clinical Modification (ICD-10-CM) code, follow these two steps: Step 1: Look

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

USMLE Step 1. Content Description and General Information

USMLE Step 1. Content Description and General Information USMLE Step 1 Content Description and General Information A Joint Program of the Federation of State Medical Boards of the United States, Inc., and the National Board of Medical Examiners This booklet updated

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

Preoperative Laboratory and Diagnostic Studies

Preoperative Laboratory and Diagnostic Studies Preoperative Laboratory and Diagnostic Studies Preoperative Labratorey and Diagnostic Studies The concept of standardized testing in all presurgical patients regardless of age or medical condition is no

More information

påçííáëü=jéçáåáåéë=`çåëçêíáìã==

påçííáëü=jéçáåáåéë=`çåëçêíáìã== påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults

More information

Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812

Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 NEWS RELEASE Media: Nikki Levy (650) 225-1729 Investor: Susan Morris (650) 225-6523 Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 GENENTECH AND BIOGEN

More information

Summary 1. Comparative-effectiveness

Summary 1. Comparative-effectiveness Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately

More information

Preconception Clinical Care for Women Medical Conditions

Preconception Clinical Care for Women Medical Conditions Preconception Clinical Care for Women All women of reproductive age are candidates for preconception care; however, preconception care must be tailored to meet the needs of the individual. Given that preconception

More information

INHERIT. The Lancet Diabetes & Endocrinology In press

INHERIT. The Lancet Diabetes & Endocrinology In press INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10

More information

Summary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06

Summary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06 CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health

More information

2009 Emergency Department

2009 Emergency Department 2009 Emergency Department Hospital Utilization Report Prepared by Vermont Department of Health Vermont Department of Banking, Insurance, Securities and Health Care Administration 2009 Vermont Emergency

More information

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further

More information

Clinical Study Report. Clinical Efficacy of the e-bright Tooth Whitening Accelerator Home Edition: a randomized placebo controlled clinical trial

Clinical Study Report. Clinical Efficacy of the e-bright Tooth Whitening Accelerator Home Edition: a randomized placebo controlled clinical trial Clinical Study Report Clinical Efficacy of the e-bright Tooth Whitening Accelerator Home Edition: a randomized placebo controlled clinical trial (Clinical Study Protocol Number: EBRIGHT-2007-01) Study

More information

Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients

Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential

More information

1. Comparative effectiveness of alemtuzumab

1. Comparative effectiveness of alemtuzumab Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued

More information

2FORMATS AND CONVENTIONS

2FORMATS AND CONVENTIONS 2FORMATS AND CONVENTIONS OF DIAGNOSIS CODING SYSTEMS Learning Outcomes After completing this chapter, students should be able to 2.1 Explain the layout of the ICD-9-CM and ICD-10-CM manuals. 2.2 Differentiate

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine)

Sponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

Adverse Events in Clinical Trials: Definitions and Documentation

Adverse Events in Clinical Trials: Definitions and Documentation Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions

More information

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has

More information

Phase of development:

Phase of development: Title of study: A randomised, placebo-controlled, double-blind, double-dummy, four-way crossover, single-centre study to investigate the effects of 2 mg and 10 mg intravenously administered NRL972 on the

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc. Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs

More information

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Technology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta350

Technology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta350 Secukinumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta350 NICE 2015. All rights reserved. Contents 1 Guidance...

More information

A: Nursing Knowledge. Alberta Licensed Practical Nurses Competency Profile 1

A: Nursing Knowledge. Alberta Licensed Practical Nurses Competency Profile 1 A: Nursing Knowledge Alberta Licensed Practical Nurses Competency Profile 1 Competency: A-1 Anatomy and Physiology A-1-1 A-1-2 A-1-3 A-1-4 A-1-5 A-1-6 A-1-7 A-1-8 Identify the normal structures and functions

More information

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2): Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information